Our top pick for
Beginners

Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Ventyx Biosciences Inc is a biotechnology business based in the US. Ventyx Biosciences shares (VTYX) are listed on the NASDAQ and all prices are listed in US Dollars. Ventyx Biosciences employs 31 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
Latest market close | $13.50 |
---|---|
52-week range | $9.50 - $26.00 |
50-day moving average | $15.24 |
200-day moving average | $15.51 |
Wall St. target price | $39.71 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.77 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $13.5 from 2022-07-05
1 week (2022-06-30) | 10.38% |
---|---|
1 month (2022-06-07) | -15.57% |
3 months (2022-04-07) | 3.05% |
6 months (2022-01-07) | -11.01% |
1 year (2021-07-03) | N/A |
---|---|
2 years (2020-07-03) | N/A |
3 years (2019-07-03) | N/A |
5 years (2017-07-03) | N/A |
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -21.02% |
Return on equity TTM | -60.26% |
Profit margin | 0% |
Book value | $5.11 |
Market capitalisation | $686.5 million |
TTM: trailing 12 months
We're not expecting Ventyx Biosciences to pay a dividend over the next 12 months.
Ventyx Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.